Serotonin and norepinephrine reuptake inhibitor antidepressants: A look through the prism of their 30-year history
Данилов Д. С.
Неврология, нейропсихиатрия, психосоматика
Т. 10, Вып. 4, С. 4-12
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.14412/2074-2711-2018-4-4-12
Аннотация:
Based on the data available in the literature, the author has first systematized in detail the main stages of the design and clinical introduction of serotonin and norepinephrine reuptake inhibitor (SNRI) antidepressants. Theoretical prerequisites for their emergence are described. The evaluation of the efficiency of depression therapy with drugs of this group in clinical trials and post-marketing studies is analyzed in the historical context. The reasons for temporary restrictions on their wide use are considered. There are data on the design of novel representatives of SNRI antidepressants. © 2018 Ima-Press Publishing House. All Rights Reserved.
Ключевые слова:
Antidepressants; Clovoxamine; Desvenlafaxine; Dual-action antidepressants; Duloxetine; History of psychopharmacology; History of psychopharmacotherapy; Levomilnacipran; Milnacipran; Serotonin and norepinephrine reuptake inhibitors; Sibutramine; Venlafaxine
Язык текста: Русский
ISSN: 2310-1342
Данилов Д. С.
Danilov D. S.
Serotonin and norepinephrine reuptake inhibitor antidepressants: A look through the prism of their 30-year history
Текст визуальный непосредственный
Неврология, нейропсихиатрия, психосоматика
ИМА-Пресс
Т. 10, Вып. 4 С. 4-12
2018
Статья
Antidepressants Clovoxamine Desvenlafaxine Dual-action antidepressants Duloxetine History of psychopharmacology History of psychopharmacotherapy Levomilnacipran Milnacipran Serotonin and norepinephrine reuptake inhibitors Sibutramine Venlafaxine
Based on the data available in the literature, the author has first systematized in detail the main stages of the design and clinical introduction of serotonin and norepinephrine reuptake inhibitor (SNRI) antidepressants. Theoretical prerequisites for their emergence are described. The evaluation of the efficiency of depression therapy with drugs of this group in clinical trials and post-marketing studies is analyzed in the historical context. The reasons for temporary restrictions on their wide use are considered. There are data on the design of novel representatives of SNRI antidepressants. © 2018 Ima-Press Publishing House. All Rights Reserved.